Dr. Cercek on the Need for Treatment Options in KRAS-Mutated mCRC

Andrea Cercek, MD
Published: Monday, Feb 10, 2020



Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the need for treatment options in KRAS-mutated metastatic colorectal cancer (mCRC).

KRAS mutations comprise about 50% of patients with mCRC. Patients with a KRAS mutation have 1 less therapeutic option because they cannot be treated with anti-EGFR therapy, said Cercek. There have been poor responses in the mCRC setting of KRAS-mutated tumors with certain treatments, such as cetuximab (Erbitux) and panitumumab (Vectibix).

Emerging studies will focus on helping this particular patient population, concludes Cercek.
SELECTED
LANGUAGE


Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the need for treatment options in KRAS-mutated metastatic colorectal cancer (mCRC).

KRAS mutations comprise about 50% of patients with mCRC. Patients with a KRAS mutation have 1 less therapeutic option because they cannot be treated with anti-EGFR therapy, said Cercek. There have been poor responses in the mCRC setting of KRAS-mutated tumors with certain treatments, such as cetuximab (Erbitux) and panitumumab (Vectibix).

Emerging studies will focus on helping this particular patient population, concludes Cercek.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x